UCB Advances Two-Drug Strategy For Myasthenia Gravis

Successful Phase III data for UCB’s C5 inhibitor zilucoplan adds to a similarly positive Phase III readout for its rozanolixizumab in December, but details are lacking. UCB is the only company with two mechanisms for MG.

UCB flag
UCB posts second successful Phase III trial in gMG in two months • Source: UCB

UCB S.A.’s complement component 5 (C5) inhibitor peptide zilucoplan hit the primary endpoint and two secondary endpoints in a Phase III study in generalized myasthenia gravis (gMG), the firm announced 4 February, helping advance its two-drug strategy for the neuromuscular autoimmune disease. UCB plans regulatory filings in the US, EU and Japan later this year for both zilucoplan and for rozanolixizumab, a neonatal Fc receptor (FcRn)-targeted antibody that met the same primary endpoint in Phase III data reported in 2021.

Chris Clark, UCB’s head of asset and commercial strategy for rare diseases, told Scrip the Brussels-headquartered firm hopes its two...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

More from R&D

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By 

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers